Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818005 | 1.00 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2A | |
| SCHEMBL12190315 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1930450 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2A | |
| SCHEMBL14587117 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2A | |
| SCHEMBL16021267 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2A | |
| SCHEMBL23977744 | 0.82 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL14382188 | 0.81 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2A | |
| SCHEMBL15308942 | 0.81 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3721581 | 0.81 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2A | |
| SCHEMBL686016 | 0.81 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171773-A1 | A substantially pure enantiomer, (R)-5-Methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; controlling factor Xa proteolytic activity to prevent thrombosis with out the risk factors affecting diabetics, heart conditions, etc | PFIZER INC | 2008-07-17 | — | — | US | disclosed |
| WO-2008065503-A1 | (R) -5-METHYL-4, 5-DIHYDRO- PYRAZOLE-1, 5-DICARBOXYLIC ACID 1- [ ( 4 -CHLOROPHENYL) AMIDE 5-{ [2-FLUORO-4- (2-OXO-2H-PYRIDIN-1-YL) -PHENYL]AMIDE) AS A FACTOR XA INHIBITOR | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171773-A1 | A substantially pure enantiomer, (R)-5-Methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; controlling factor Xa proteolytic activity to prevent thrombosis with out the risk factors affecting diabetics, heart conditions, etc | F2, PLG, PLAT | ALDH1A1 1688/4885MEN1 4033/4885KMT2A 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.